# Artelo Biosciences Advances Peripheral Cannabinoid Agonists for Glaucoma > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/peripheral-cannabinoid-receptor-agonists-glaucoma/ > **Published:** 2026-03-18T21:12:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:38-04:00 > **Clinical Summary:** Explore advances in peripheral cannabinoid receptor agonists glaucoma research focusing on ART12.11 and intraocular pressure reduction. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologySafety Why This Matters Clinicians managing glaucoma patients need to monitor emerging cannabinoid therapies as potential adjunctive treatments, since intraocular pressure reduction is a primary therapeutic goal and novel mechanisms may offer alternatives for patients who fail or cannot tolerate standard agents. This clinical trial partnership suggests [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) is advancing toward regulatory evaluation, which will require ophthalmologists to understand efficacy, safety, and appropriate patient selection for these agents. Patients with refractory glaucoma should be informed that investigational cannabinoid options may become available, though they should continue conventional therapy until clinical evidence demonstrates superiority or non-inferiority. Clinical Summary Artelo Biosciences has entered into a research agreement to evaluate ART12.11, a peripherally selective synthetic cannabinoid, for treating glaucoma and ocular hypertension in collaboration with Glaucoma UK and the HSC R&D Division. This development represents a potentially significant advance for glaucoma management, as cannabinoid compounds have shown promise in reducing intraocular pressure, a key therapeutic target in glaucoma treatment. The peripheral selectivity of ART12.11 is particularly noteworthy because it may reduce central nervous system [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) associated with non-selective cannabinoids, potentially improving tolerability for patients requiring long-term glaucoma therapy. While the agreement marks an important step toward clinical evaluation, clinicians should recognize that these findings remain investigational and not yet ready for clinical practice. For now, patients with glaucoma should continue conventional pharmacologic therapies proven to reduce intraocular pressure, though this research may offer an alternative option if future studies demonstrate safety and efficacy comparable to existing treatments. Dr. Caplan’s Take “What excites me about peripheral cannabinoid selectivity isn’t the stock price, it’s that we may finally have a way to leverage cannabis’s genuine intraocular pressure-lowering effects without the cognitive side effects that have limited clinical adoption for two decades.” Clinical Perspective While early-stage investigations of peripheral cannabinoid receptor agonists for glaucoma management warrant attention given the substantial disease burden and limited treatment options, clinicians should recognize that stock market enthusiasm rarely correlates with clinical efficacy or regulatory success. The lack of published peer-reviewed data in this summary makes it premature to assess whether this compound offers meaningful advantages over existing topical or systemic therapies, and the peripheral selectivity claim requires validation regarding both safety and intraocular pressure reduction. Confounders such as study design, patient population characteristics, dosing regimens, and whether this represents early preclinical work versus late-stage trials significantly influence interpretability. Until robust efficacy and safety data emerge in peer-reviewed literature, current glaucoma management guidelines should remain unchanged, but clinicians might reasonably monitor for future publications to evaluate whether cannabinoid-based therapies could eventually expand the therapeutic armamentarium for patients with inadequ 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Artelo+Biosciences+stock+surges+on+glaucoma+study+agreement+-+Investing.com+%40drcaplan&url=https%3A%2F%2Fm.investing.com%2Fnews%2Fstock-market-news%2Fartelo-biosciences-stock-surges-on-glaucoma-study-agreement-93CH-4568960%3FampMode%3D1)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fm.investing.com%2Fnews%2Fstock-market-news%2Fartelo-biosciences-stock-surges-on-glaucoma-study-agreement-93CH-4568960%3FampMode%3D1)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Artelo+Biosciences+stock+surges+on+glaucoma+study+agreement+-+Investing.com+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fm.investing.com%2Fnews%2Fstock-market-news%2Fartelo-biosciences-stock-surges-on-glaucoma-study-agreement-93CH-4568960%3FampMode%3D1)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://m.investing.com/news/stock-market-news/artelo-biosciences-stock-surges-on-glaucoma-study-agreement-93CH-4568960?ampMode=1](https://m.investing.com/news/stock-market-news/artelo-biosciences-stock-surges-on-glaucoma-study-agreement-93CH-4568960?ampMode=1) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study …](https://cedclinic.com/cannabinoid-based-glaucoma-treatments-emerging-study/) Learn about Artelo Biosciences' strategic expansion into the glaucoma market with a fully funded study targeting innovative treatments. [Read More](https://cedclinic.com/cannabinoid-based-glaucoma-treatments-emerging-study/) [Artelo expands into glaucoma with funded study – ARTL – Stock Titan](https://cedclinic.com/cb2-receptor-targeting-glaucoma-study-artelo-expands/) Discover how Artelo's funded glaucoma study could impact future therapies and market dynamics in ocular health. [Explore Article](https://cedclinic.com/cb2-receptor-targeting-glaucoma-study-artelo-expands/) [Study Finds Cannabis Compounds May Help Reduce Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Explore research on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) showing potential benefits beyond glaucoma, including [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) reduction. [Learn More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).